^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Excerpt:
...- Confirmed diagnosis of ER positive/Her2-negative breast cancer...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1stline chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer

Published date:
11/17/2020
Excerpt:
...Median PFS was 29.3 months (95%CI 14.605-43.995) in endocrine maintenance therapy group and 14.8 months (95%CI 7.445-22.155) in capecitabine maintenance therapy group. For HR+ and HER2-MBC, after 1 st-line salvage combined chemotherapy, ET maintenance has a better survival benefits than CT,especially for ET-sensitive and non-visceral involved cases.
Trial ID: